Popular Articles
Cellulite Treatment

CuraGen To Present CR011-vcMMAE Data At ASCO
CuraGen Corporation (Nasdaq: CRGN) announced plans for three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
generic viagra online
New Strategy Proposed For Designing Antibody-Based HIV Vaccine
Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Attempts to create a vaccine that induces antibodies that prevent HIV infection or disease, however, have so far been unsuccessful. But several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine, according to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and colleagues.
News of the day
Test Detects Molecular Marker Of Aging In Humans
In 2004, researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center announced a crucial discovery in the understanding of cellular aging. They found that as cells and tissues age, the expression of a key protein, called p16INK4a, dramatically increases in most mammalian organs. Because p16INK4a is a tumor suppressor protein, cancer researchers are interested in its role in cellular aging and cancer prevention.
Mental Health

New Lasers Drive Powerful Applications

Telecoms, healthcare and display technology will be the major beneficiaries of a new generation of semiconductor lasers developed in a massive European research effort. Better cancer treatment, wider bandwidth and smaller, better displays could be on their way. The Brighter project, which is co-funded by the European Union, has set a series of world firsts in lab-based records for semiconductor lasers in the red, infrared and green spectra. These results will not languish on the testing bench. The Brighter project began its work with three, hugely important applications already in its sights. One of the most compelling is a new type of cancer treatment and imaging enabled by semiconductor lasers developed by Brighter. Photodynamic therapy is a very promising treatment for cancer patients that can maximise the benefits, while minimising the harm, from chemotherapy. Photodynamic therapy works by introducing an inactive chemotherapy drug into the patient. This drug then seeks out and attaches itself to cancer cells. The drug is then activated by laser. It is a very promising and potentially highly effective treatment that only releases drugs at cancer cell sites, reducing the side effects and enhancing the impact on tumours. Clinical studies In Brighter, the scientists developed a range of lasers for different elements of the treatment. Powerful and highly reliable red lasers one at 635nm another at 650nm were developed to activate different drugs. Meanwhile, a high-powered blue laser provides fluorescent spectroscopy, to show that the drug has reached the target site. Finally, a high-powered ultraviolet laser provides auto-fluorescent imaging of the cancer site. Both clinical and experimental animal studies are currently underway for different elements of the treatment, and any promising results are likely to be commercialised. "We have end users, medical doctors, working within the project to ensure that the technologies developed are best suited to their needs," explains Michel Krakowski, coordinator of the Brighter project. Telecommunications, too, is a compelling application and Brighter has developed a range of elements to respond to pressing needs in the sector. "We have developed a range of lasers and their associated technology to considerably boost bandwidth across optical fibres for data-intensive telecoms," explains Krakowski. The upshot is more bandwidth in the same pipe, an application that will go a long way to meeting the challenge of rising demand for bandwidth. This was a non-trivial problem. In addition to developing a semiconductor of the required quality and power, the Brighter project had to develop methods for coupling lasers together, to create an even more powerful light , and then coupling the light to optical fibres. New products In displays, Brighter hopes to usher in new products or better, smaller and more efficient versions of existing products. Current applications in sight are extremely small, powerful and efficient light projectors for film, presentations and other applications, such as heads-up-displays and mobile projectors. The technology could even be adapted for use with mobile phones, allowing them to project extremely high quality video for television applications, for example. In the coming months, the high-performance red and green laser modules developed in the Brighter project will be tested for feasibility for display applications. For all these applications, Brighter has developed and perfected a vast range of fabrication and design techniques for semiconductor lasers, including doping, deposition, and external cavities on the semiconductor material to "tune" the laser, stabilise it, or couple it with other lasers, depending on the required results. Beyond theory and applications Brighter"s work did not stop at theory or application, either. The team engaged in a surprisingly large-scale effort to disseminate new knowledge gained on laser production, characterisation, design and fabrication. These educational materials cover a vast range of the latest thinking on lasers and present them in a series of tutorials and presentations on the project and its work. The aim here is to make effective materials available for students and others, and to expand the pool of expertise in this field in Europe and around the world. Brighter"s online materials and CD-ROMs are freely available to anyone. There are 46 PhD students involved 21 directly funded through Brighter with a further 25 contributing to and/or benefiting from the project, notes Krakowski. "We made a special effort with dissemination because we wanted to spread the impact of our work and raise the profile of the field." The EU-funded project is now expected to end in January 2010, by which time it plans to have fully demonstrated Europe"s expertise in semiconductor laser technology, and its ability to create compelling new devices over the next two to five years. The Brighter integrated project has received funding from the ICT strand of the EU"s Sixth Framework Programme for research. ICT Results


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):